Mostrar el registro sencillo del ítem
dc.contributor.author | Garrido-Cano, Iris | es_ES |
dc.contributor.author | Adam-Artigues, Anna | es_ES |
dc.contributor.author | Lameirinhas, Ana | es_ES |
dc.contributor.author | Blandez, Juan F. | es_ES |
dc.contributor.author | Candela-Noguera, Vicente | es_ES |
dc.contributor.author | Lluch, Ana | es_ES |
dc.contributor.author | Bermejo, Begoña | es_ES |
dc.contributor.author | Sancenón Galarza, Félix | es_ES |
dc.contributor.author | Cejalvo, Juan Miguel | es_ES |
dc.contributor.author | Martínez-Máñez, Ramón | es_ES |
dc.contributor.author | Eroles, Pilar | es_ES |
dc.date.accessioned | 2024-04-11T11:58:38Z | |
dc.date.available | 2024-04-11T11:58:38Z | |
dc.date.issued | 2023-08 | es_ES |
dc.identifier.issn | 1944-8244 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/203426 | |
dc.description.abstract | [EN] Despite advancesin breast cancer treatment, it remainsthe leadingcause of cancer-related death in women worldwide. In this context,microRNAs have emerged as potential therapeutic targets but stillpresent some limitations for in vivo applications.Particularly, miR-200c-3p is a well-known tumor suppressor microRNAthat inhibits tumor progression and metastasis in breast cancer throughdownregulating ZEB1 and ZEB2. Basedon the above, we describe the design and validation of a nanodeviceusing mesoporous silica nanoparticles for miR-200c-3p delivery forbreast cancer treatment. We demonstrate the biocompatibility of thesynthesized nanodevices as well as their ability to escape from endosomes/lysosomesand inhibit tumorigenesis, invasion, migration, and proliferationof tumor cells in vitro. Moreover, tumor targetingand effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mousemodel, and the therapeutic efficacy is also evidenced by a decreasein tumor size and lung metastasis, while showing no signs of toxicity.Overall, our results provide evidence that miR-200c-3p-loaded nanoparticlesare a potential strategy for breast cancer therapy and a safe andeffective system for tumor-targeted delivery of microRNAs. | es_ES |
dc.description.sponsorship | This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund A way of doing Europe. Also, this study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGeneration EU(PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was also supported by CIBER Consorcio Centro de Investigación Biomédica en Red CIBER-BBN(CB07/01/2012), CIBERONC(CB16/12/00481), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. This work was also supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351) .I.G.-C. was funded by Margarita Salas post doctoral grant (European Union-Nextgeneration EU). A.A.-A. and A.L. were funded by Asociación Española Contra el Cancer.J.F.B. was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support 'Sara Borrell' (CD19/00038). V.C.-N. was funded by Ministerio de Ciencia e Innovacio¿n (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM) | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | American Chemical Society | es_ES |
dc.relation.ispartof | ACS Applied Materials & Interfaces | es_ES |
dc.rights | Reconocimiento (by) | es_ES |
dc.subject | Mesoporous silica nanoparticles | es_ES |
dc.subject | Breast cancer | es_ES |
dc.subject | MicroRNA | es_ES |
dc.subject | Therapy | es_ES |
dc.subject | Targeted delivery | es_ES |
dc.subject.classification | QUIMICA ORGANICA | es_ES |
dc.subject.classification | QUIMICA INORGANICA | es_ES |
dc.title | Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1021/acsami.3c07541 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-126304OB-C41/ES/NUEVOS MATERIALES Y SONDAS PARA EL RECONOCIMIENTO, LIBERACION DE FARMACOS, NANOMOTORES Y COMUNICACION/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//MFA%2F2022%2F049/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//CIPROM%2F2021%2F007/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//CD19%2F00038/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//PI21%2F01351/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//PI18%2F01219/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00481//CANCER/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MICINN//PRTR-C17.I1/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MICINN//CB07%2F01%2F2012//Bioingeniería, biomateriales y nanomedicina/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials | es_ES |
dc.description.bibliographicCitation | Garrido-Cano, I.; Adam-Artigues, A.; Lameirinhas, A.; Blandez, JF.; Candela-Noguera, V.; Lluch, A.; Bermejo, B.... (2023). Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy. ACS Applied Materials & Interfaces. 15(32):38323-38334. https://doi.org/10.1021/acsami.3c07541 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1021/acsami.3c07541 | es_ES |
dc.description.upvformatpinicio | 38323 | es_ES |
dc.description.upvformatpfin | 38334 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 15 | es_ES |
dc.description.issue | 32 | es_ES |
dc.identifier.pmid | 37549382 | es_ES |
dc.identifier.pmcid | PMC10436244 | es_ES |
dc.relation.pasarela | S\508702 | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación | es_ES |
dc.contributor.funder | Universitat Politècnica de València | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |
dc.contributor.funder | Sociedad Española de Oncología Médica | es_ES |